Abstract
Introduction: The concept of occult breast carcinoma (OBC) was first described in 1907 by Halsted, who described this type of breast cancer to arise from small, undetectable tumours in the breast that had already metastasized to the lymph nodes. Although the breast is the most likely site for the primary tumour, non-palpable breast cancer presenting as an axillary metastasis has been reported, but with a low frequency of less than 0.5% of all breast cancers. OBC represents a complex diagnostic and therapeutic dilemma. Considering its rarity, clinicopathological information is still limited.
Case Report: A 44-year-old patient presented to the emergency room with an extensive axillary mass as the first manifestation. Conventional evaluation of the breast with mammography and ultrasound was unremarkable. However, a breast MRI confirmed the presence of conglomerate axillary nodes. A supplementary whole-body PET-CT established the axillary conglomerate with a malignant behaviour with SUVmax of 19.3. The primary tumour was not detected in the breast tissue of the patient, confirming the diagnosis of OBC. Immunohistochemical results showed positive receptors for estrogen and progesterone.
Conclusion: Although OBC is a rare diagnosis, its existence is a possibility in a patient with breast cancer. Mammography and breast ultrasound with unremarkable findings but with high clinical suspicion should be supplemented with additional imaging methods, such as MRI and PET-CT, emphasizing the appropriate pre-treatment evaluation.
[1]
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers 2021; 13(17): 4287.
[http://dx.doi.org/10.3390/cancers13174287] [PMID: 34503097]
[http://dx.doi.org/10.3390/cancers13174287] [PMID: 34503097]
[2]
Toss A, Moscetti L, Cascinu S. Occult breast cancer: The uncommon presentation of a common disease. Chin Clin Oncol 2019; 8(S1): S10.
[http://dx.doi.org/10.21037/cco.2019.01.06] [PMID: 30823842]
[http://dx.doi.org/10.21037/cco.2019.01.06] [PMID: 30823842]
[3]
Zhao Z, Zhang T, Yao Y, Lu X. Clinicopathological characteristics and treatment outcomes of occult breast cancer: A population-based study. BMC Surg 2022; 22(1): 143.
[http://dx.doi.org/10.1186/s12893-022-01472-8] [PMID: 35430796]
[http://dx.doi.org/10.1186/s12893-022-01472-8] [PMID: 35430796]
[4]
Saccarelli CR, Bitencourt AGV, Morris EA. Breast cancer screening in high-risk women: Is mri alone enough? J Natl Cancer Inst 2020; 112(2): 121-2.
[http://dx.doi.org/10.1093/jnci/djz130] [PMID: 31233125]
[http://dx.doi.org/10.1093/jnci/djz130] [PMID: 31233125]
[5]
Akhtar K, Singh S, Siddiqui S, Ahmad S. FNAB of metastatic lesions with special reference to clinicopathological analysis of primary site in cases of epithelial and non-epithelial tumors. J Cytol 2011; 28(2): 61-5.
[http://dx.doi.org/10.4103/0970-9371.80740] [PMID: 21713149]
[http://dx.doi.org/10.4103/0970-9371.80740] [PMID: 21713149]
[6]
Ofri A, Moore K. Occult breast cancer: Where are we at? Breast 2020; 54: 211-5.
[http://dx.doi.org/10.1016/j.breast.2020.10.012] [PMID: 33130487]
[http://dx.doi.org/10.1016/j.breast.2020.10.012] [PMID: 33130487]
[7]
Costantini M, Montella RA, Fadda MP, et al. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): Role of contrast-enhanced spectral mammography (CESM) in detecting occult breast cancer. J Pers Med 2021; 11(6): 465.
[http://dx.doi.org/10.3390/jpm11060465] [PMID: 34070278]
[http://dx.doi.org/10.3390/jpm11060465] [PMID: 34070278]
[8]
Halsted WS. I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907; 46(1): 1-19.
[http://dx.doi.org/10.1097/00000658-190707000-00001] [PMID: 17861990]
[http://dx.doi.org/10.1097/00000658-190707000-00001] [PMID: 17861990]
[9]
Hüppe JR. [The way to the detection of occult breast carcinoma. An appeal to radiologists, surgeons and pathologists for team-work]. Radiologe 1973; 13(11): 477-81.
[PMID: 4779089]
[PMID: 4779089]
[10]
Patchefsky AS, Potok J, Hoch WS, Libshitz HI. Increased detection of occult breast carcinoma after more thorough histologic examination of breast biopsies. Am J Clin Pathol 1973; 60(6): 799-804.
[http://dx.doi.org/10.1093/ajcp/60.6.799] [PMID: 4357121]
[http://dx.doi.org/10.1093/ajcp/60.6.799] [PMID: 4357121]
[11]
Clarijs WW, van Deelen-Willems M, Hendriks JH, Lubbers EJ, Schmidt WJ. [The occult breast carcinoma]. Ned Tijdschr Geneeskd 1977; 121(13): 526-9.
[PMID: 846589]
[PMID: 846589]
[12]
Snyderman RK, Lizardo JG. Statistical study of malignancies found before, during, or after routine breast plastic operations. Plast Reconstr Surg 1960; 25(3): 253-6.
[http://dx.doi.org/10.1097/00006534-196003000-00006] [PMID: 13832341]
[http://dx.doi.org/10.1097/00006534-196003000-00006] [PMID: 13832341]
[13]
Pitanguy I, Torres ET. Histopathological aspects of mammary gland tissue in cases of plastic surgery of breast. Br J Plast Surg 1964; 17: 297-302.
[http://dx.doi.org/10.1016/S0007-1226(64)80046-1] [PMID: 14191134]
[http://dx.doi.org/10.1016/S0007-1226(64)80046-1] [PMID: 14191134]
[14]
Baskota SU, Qazi D, Chandra A, Vohra P. Comprehensive review of metastatic breast carcinoma in cytology specimens. J Mol Pathol 2022; 3(4): 293-306.
[http://dx.doi.org/10.3390/jmp3040025]
[http://dx.doi.org/10.3390/jmp3040025]
[15]
Walker GV, Smith GL, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer 2010; 116(17): 4000-6.
[http://dx.doi.org/10.1002/cncr.25197] [PMID: 20564117]
[http://dx.doi.org/10.1002/cncr.25197] [PMID: 20564117]
[16]
Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012; 379(9824): 1428-35.
[http://dx.doi.org/10.1016/S0140-6736(11)61178-1] [PMID: 22414598]
[http://dx.doi.org/10.1016/S0140-6736(11)61178-1] [PMID: 22414598]
[17]
Sanuki-Fujimoto N, Takeda A, Amemiya A, et al. Pattern of tumor recurrence in initially nonmetastatic breast cancer patients. Cancer 2008; 113(4): 677-82.
[http://dx.doi.org/10.1002/cncr.23612] [PMID: 18613072]
[http://dx.doi.org/10.1002/cncr.23612] [PMID: 18613072]
[18]
Zhang D, Zhai J, Li L, Wu Y, Ma F, Xu B. Prognostic factors and a model for occult breast cancer: A population-based cohort study. J Clin Med 2022; 11(22): 6804.
[http://dx.doi.org/10.3390/jcm11226804] [PMID: 36431280]
[http://dx.doi.org/10.3390/jcm11226804] [PMID: 36431280]
[19]
Di Micco R, Santurro L, Gasparri ML, et al. Rare sites of breast cancer metastasis: A review. Transl Cancer Res 2019; 8(S5): S518-52.
[http://dx.doi.org/10.21037/tcr.2019.07.24] [PMID: 35117130]
[http://dx.doi.org/10.21037/tcr.2019.07.24] [PMID: 35117130]
[20]
Camarneiro R, Ferreira Á, Barros M, Brito e Melo M. Occult breast cancer presenting as axillary lymphadenopathy – Case Report. Int J Surg Case Rep 2022; 99: 107677.
[http://dx.doi.org/10.1016/j.ijscr.2022.107677] [PMID: 36162357]
[http://dx.doi.org/10.1016/j.ijscr.2022.107677] [PMID: 36162357]
[21]
Zhang Y, Wu D, Zhao B, et al. Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature. World J Clin Cases 2021; 9(4): 919-26.
[http://dx.doi.org/10.12998/wjcc.v9.i4.919] [PMID: 33585640]
[http://dx.doi.org/10.12998/wjcc.v9.i4.919] [PMID: 33585640]
[22]
Kikumori K, Oshima K, Yanagawa T, et al. [Occult breast cancer presenting with a swelling axillary lymph node-a case report]. Gan To Kagaku Ryoho 2021; 48(13): 1849-51.
[PMID: 35045425]
[PMID: 35045425]
[23]
Frattaroli FM, Carrara A, Conte AM, Pappalardo G. Axillary metastasis as first symptom of occult breast cancer: A case report. Tumori 2002; 88(6): 532-4.
[http://dx.doi.org/10.1177/030089160208800620] [PMID: 12597153]
[http://dx.doi.org/10.1177/030089160208800620] [PMID: 12597153]
[24]
Tamiolakis D, Antoniou C. Axillary nodal metastasis of occult breast primary cancer. Chirurgia 2008; 103(4): 467-71.
[PMID: 18780622]
[PMID: 18780622]
[25]
Monib S, Pakdemirli E, Chong K. Mammographically and MRI occult breast cancer. BMJ Case Rep 2019; 12(6): e230190.
[http://dx.doi.org/10.1136/bcr-2019-230190] [PMID: 31253664]
[http://dx.doi.org/10.1136/bcr-2019-230190] [PMID: 31253664]
[26]
Vomáčková K, Zlámalová N, Veverková L, Spáčilová K, Donociková B, Kolečková M. Occult breast cancer: A case report and current management of treatment. Rozhl Chir 2022; 101(3): 138-42.
[PMID: 35387471]
[PMID: 35387471]
[27]
Wang X, Zhao Y, Cao X. Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases. Breast J 2010; 16(1): 32-7.
[http://dx.doi.org/10.1111/j.1524-4741.2009.00848.x] [PMID: 20465598]
[http://dx.doi.org/10.1111/j.1524-4741.2009.00848.x] [PMID: 20465598]
[28]
Mann RM, Cho N, Moy L. Breast MRI: State of the Art. Radiology 2019; 292(3): 520-36.
[http://dx.doi.org/10.1148/radiol.2019182947] [PMID: 31361209]
[http://dx.doi.org/10.1148/radiol.2019182947] [PMID: 31361209]
[29]
Mainiero MB, Moy L, Baron P, et al. ACR appropriateness criteria ® breast cancer screening. J Am Coll Radiol 2017; 14(11): S383-90.
[http://dx.doi.org/10.1016/j.jacr.2017.08.044] [PMID: 29101979]
[http://dx.doi.org/10.1016/j.jacr.2017.08.044] [PMID: 29101979]
[30]
Shawky M, Ali ZAE, Hashem DH, Houseni M. Role of positron-emission tomography/computed tomography (PET/CT) in breast cancer. Egypt J Radiol Nucl Med 2020; 51(1): 125.
[http://dx.doi.org/10.1186/s43055-020-00244-9]
[http://dx.doi.org/10.1186/s43055-020-00244-9]
[31]
Homesh NA, Issa MA, El-Sofiani HA. The diagnostic accuracy of fine needle aspiration cytology versus core needle biopsy for palpable breast lump(s). Saudi Med J 2005; 26(1): 42-6.
[PMID: 15756351]
[PMID: 15756351]
[32]
Kittaneh M, Montero AJ, Glück S. Molecular profiling for breast cancer: A comprehensive review. Biomark Cancer 2013; 5: BIC.S9455.
[http://dx.doi.org/10.4137/BIC.S9455] [PMID: 24250234]
[http://dx.doi.org/10.4137/BIC.S9455] [PMID: 24250234]
[33]
de Andrade JM, Marana HRC, Filho JMS, Murta EFC, Velludo MASL, Bighetti S. Differential diagnosis of axillary masses. Tumori 1996; 82(6): 596-9.
[http://dx.doi.org/10.1177/030089169608200617] [PMID: 9061072]
[http://dx.doi.org/10.1177/030089169608200617] [PMID: 9061072]
[34]
Dialani V, James DF, Slanetz PJ. A practical approach to imaging the axilla. Insights Imaging 2015; 6(2): 217-29.
[http://dx.doi.org/10.1007/s13244-014-0367-8] [PMID: 25534139]
[http://dx.doi.org/10.1007/s13244-014-0367-8] [PMID: 25534139]
[35]
Yamaguchi H, Ishikawa M, Hatanaka K, Uekusa T, Ishimaru M, Nagawa H. Occult breast cancer presenting as axillary metastases. Breast 2006; 15(2): 259-62.
[http://dx.doi.org/10.1016/j.breast.2005.04.018] [PMID: 15996865]
[http://dx.doi.org/10.1016/j.breast.2005.04.018] [PMID: 15996865]
[36]
Altan E, Altundag K. Clinical and pathological characteristics of occult breast cancer and review of the literature. J BUON 2011; 16(3): 434-6.
[PMID: 22006745]
[PMID: 22006745]
[37]
Lu S, Liu H. [Diagnosis and treatment of occult breast cancer in 44 cases]. Zhonghua Zhong Liu Za Zhi 2011; 33(7): 550-2.
[PMID: 22093638]
[PMID: 22093638]
[38]
Zhong Y, Sun Q, Huang HY, et al. [Diagnosis and treatment of occult breast cancer: Report of 23 cases]. Zhonghua Zhong Liu Za Zhi 2010; 32(9): 716-8.
[PMID: 21122392]
[PMID: 21122392]
[39]
Kim H, Park W, Kim SSS, et al. Prognosis of patients with axillary lymph node metastases from occult breast cancer: Analysis of multicenter data. Radiat Oncol J 2021; 39(2): 107-12.
[http://dx.doi.org/10.3857/roj.2021.00241] [PMID: 34619827]
[http://dx.doi.org/10.3857/roj.2021.00241] [PMID: 34619827]
[40]
Ge LP, Liu XY, Xiao Y, et al. Clinicopathological characteristics and treatment outcomes of occult breast cancer: A SEER population-based study. Cancer Manag Res 2018; 10: 4381-91.
[http://dx.doi.org/10.2147/CMAR.S169019] [PMID: 30349371]
[http://dx.doi.org/10.2147/CMAR.S169019] [PMID: 30349371]
[41]
Sohn G, Son BH, Lee SJ, et al. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: A nationwide retrospective study. J Surg Oncol 2014; 110(3): 270-4.
[http://dx.doi.org/10.1002/jso.23644] [PMID: 24863883]
[http://dx.doi.org/10.1002/jso.23644] [PMID: 24863883]
[42]
He M, Tang LC, Yu KD, et al. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. Eur J Surg Oncol 2012; 38(11): 1022-8.
[http://dx.doi.org/10.1016/j.ejso.2012.08.022] [PMID: 22959166]
[http://dx.doi.org/10.1016/j.ejso.2012.08.022] [PMID: 22959166]
[43]
Hainsworth JD, Greco FA. Management of patients with cancer of unknown primary site. Oncology 2000; 14: 563-74.
[44]
Mantiero M, Faggioni G, Menichetti A, Fassan M, Guarneri V, Conte P. Gastric linitis plastica and peritoneal carcinomatosis as first manifestations of occult breast carcinoma: A case report and literature review. Case Rep Oncol Med 2018; 2018: 1-4.
[http://dx.doi.org/10.1155/2018/4714708] [PMID: 30073103]
[http://dx.doi.org/10.1155/2018/4714708] [PMID: 30073103]
[45]
Altundag K. Metastatic occult breast carcinoma to gallbladder initially presenting as acute cholecystitis. J BUON 2021; 26(2): 634.
[PMID: 34077016]
[PMID: 34077016]
[46]
Booij J, Adam JA, van Eerde MS, Bronner IM. Paraneoplastic cerebellar syndrome presented as cerebellar hypermetabolism in a patient with occult breast carcinoma. Clin Nucl Med 2022; 47(2): 130-2.
[http://dx.doi.org/10.1097/RLU.0000000000004016] [PMID: 35006107]
[http://dx.doi.org/10.1097/RLU.0000000000004016] [PMID: 35006107]
[47]
Costa RLB, Costa-Filho RB, Rosa M, Czerniecki BJ. Occult breast carcinoma presenting as scalp metastasis. Case Rep Oncol 2017; 10(3): 992-7.
[http://dx.doi.org/10.1159/000484346] [PMID: 29279704]
[http://dx.doi.org/10.1159/000484346] [PMID: 29279704]
[48]
Vadivelu R, Drew S. Phalangeal metastasis secondary to an occult breast carcinoma. Arch Orthop Trauma Surg 2002; 122(9): 530-1.
[http://dx.doi.org/10.1007/s00402-002-0399-2] [PMID: 12483336]
[http://dx.doi.org/10.1007/s00402-002-0399-2] [PMID: 12483336]
[49]
Uppal HS, Ayshford CA, Wilson F. Sudden onset bilateral sensorineural hearing loss: A manifestation of occult breast carcinoma. J Laryngol Otol 2001; 115(11): 907-10.
[http://dx.doi.org/10.1258/0022215011909323] [PMID: 11779308]
[http://dx.doi.org/10.1258/0022215011909323] [PMID: 11779308]
